CRF neurons of the extended amygdala and alcohol drinking

扩展杏仁核的 CRF 神经元和饮酒

基本信息

批准号：
10189451
负责人：
ROBERT O. MESSING
金额：
$ 34.65万
依托单位：
UNIVERSITY OF TEXAS AT AUSTIN
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-07-20 至 2024-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10189451
关键词：
Address Affinity Alcohol consumption Amino Acids Amygdaloid structure Animals Automobile Driving Bacterial Artificial Chromosomes Behavior Behavioral Biology Brain region CRH gene Corticotropin-Releasing Hormone Corticotropin-Releasing Hormone Receptors Dorsal Enterobacteria phage P1 Cre recombinase Ethanol Ethanol dependence FDA approved Gene Expression Profiling Genetic Goals Growth Associated Protein 43 Heavy Drinking Human Hypothalamic structure Immunoprecipitation Intervention Knowledge Laboratories Lateral Limbic System Literature Maintenance Messenger RNA Modeling Molecular Naltrexone Negative Reinforcements Neurons Neuropeptides Neurotensin Neurotransmitters Peptides Pharmaceutical Preparations Pharmacology Phase Phenotype Physiological Play Population Procedures Property Public Health RNA Interference Rattus Relapse Ribosomes Rodent Role Somatostatin Source Stress Structure of terminal stria nuclei of preoptic region Testing Therapeutic Transgenic Organisms Translating Viral Vector Wistar Rats Withdrawal acamprosate alcohol abuse therapy alcohol craving alcohol measurement alcohol use disorder base designer receptors exclusively activated by designer drugs drinking drug testing experimental study gamma-Aminobutyric Acid knock-down neurobiological mechanism next generation pro-corticotropin releasing hormone prodynorphin promoter psychosocial release factor response sex sexual dimorphism small hairpin RNA success synergism tool transcriptome transcriptome sequencing

项目摘要

PROJECT SUMMARY Alcohol use disorder is a major public health problem. To date, available treatment options are limited to psychosocial intervention, three FDA approved medications (disulfuram, acamprosate, and naltrexone) and a few drugs approved for other indications, all with relatively small effect sizes. There is a clear need for additional treatments based on a deeper understanding of neurobiological mechanisms. Corticotrophin releasing factor (CRF) is a 41-amino acid neuropeptide produced mainly by neurons of the paraventricular hypothalamus, central amygdala (CeA), and bed nucleus of the stria terminalis (BNST) where it plays an important role in behavioral and physiological responses to stress. CRF has been long implicated in driving excessive ethanol consumption through prior studies that used CRF receptor antagonists in rodents. However, recent attempts to test CRF receptor antagonists as treatments for alcohol craving in humans have been disappointing. Part of this lack of success may be due to inadequate drug-like properties of some compounds and by a need for different human laboratory models that test drug effects on withdrawal and negative reinforcement in dependent subjects. Another reason may be due to the fact that CRF is released from neurons with other peptides and neurotransmitters that may act in synergy to drive excessive drinking. Understanding which of these co-released factors is important necessitates a different strategy that focuses on the CRF neurons themselves rather than on CRF receptors. The lack of genetic access to subpopulations of CRF neurons has made it difficult to study the biology of CRF neurons, the sources of CRF in different brain regions, and the circuitry underlying CRF-regulated behaviors. To fill this gap, we generated a BAC transgenic Wistar rat line in which Cre recombinase is expressed from the Crh gene promoter to enable genetic access to CRF neurons. In this project, we will use these rats to pursue the hypothesis that as animals develop ethanol dependence, CRF neurons in the CeA and BNST promote ethanol consumption through the coordinated release of GABA, CRF, and other neuropeptides. We will examine this hypothesis by selectively activating or inhibiting these neuronal populations and their projections using chemogenetic tools, and we will address the relative importance of the different transmitters and modulators released from these neurons using Cre-dependent RNA interference. Finally, we will investigate the role of repeated ethanol consumption on the transcriptome of these CRF neuronal populations to understand how ethanol changes their phenotype, which should provide us with important new clues as to how they drive excessive drinking. !

项目概要酒精使用障碍是一个重大的公共卫生问题。迄今为止，可用的治疗方案仅限于心理社会干预，三种 FDA 批准的药物（双硫仑、阿坎酸和纳曲酮）和一种很少有药物被批准用于其他适应症，而且所有药物的效果都相对较小。有一个明确的需要基于对神经生物学机制的更深入理解的额外治疗。促肾上腺皮质激素释放因子（CRF）是一种由 41 个氨基酸组成的神经肽，主要由室旁神经元产生下丘脑、中央杏仁核 (CeA) 和终纹床核 (BNST) 发挥着重要作用在对压力的行为和生理反应中发挥重要作用。 CRF长期与驾驶有关先前在啮齿类动物中使用 CRF 受体拮抗剂的研究表明过量乙醇消耗。然而，最近尝试测试 CRF 受体拮抗剂作为人类酒精渴望的治疗方法令人失望。未能取得成功的部分原因可能是某些化合物的类药特性不足以及需要不同的人体实验室模型来测试药物对戒断和阴性的影响依赖科目的强化。另一个原因可能是由于CRF是从神经元与其他肽和神经递质可能协同作用，导致过度饮酒。了解这些共同发布的因素中哪些是重要的，需要采取不同的策略，重点关注 CRF 神经元本身而不是 CRF 受体。由于缺乏 CRF 神经元亚群的遗传途径，使得研究 CRF 的生物学变得困难神经元、不同大脑区域 CRF 的来源以及 CRF 调节行为的电路。为了填补这一空白，我们构建了 BAC 转基因 Wistar 大鼠系，其中 Cre 重组酶由 Crh 基因启动子能够对 CRF 神经元进行遗传访问。在这个项目中，我们将利用这些老鼠来追寻假设当动物产生乙醇依赖性时，CeA 和 BNST 中的 CRF 神经元会促进通过协调释放 GABA、CRF 和其他神经肽来消耗乙醇。我们将通过选择性激活或抑制这些神经元群体及其预测来检验这一假设使用化学遗传学工具，我们将解决不同递质和使用 Cre 依赖性 RNA 干扰从这些神经元中释放调节剂。最后，我们将调查重复乙醇消耗对这些 CRF 神经元群转录组的作用了解乙醇如何改变其表型，这应该为我们提供重要的新线索他们导致过度饮酒。！

项目成果

期刊论文数量（4）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target?

酒精使用障碍中的促肾上腺皮质激素释放因子受体 1：仍然是有效的药物靶标吗？

DOI：
发表时间：
2017-12
期刊：
影响因子：
0
作者：
Pomrenze, Matthew B;Fetterly, Tracy L;Winder, Danny G;Messing, Robert O
通讯作者：
Messing, Robert O

Corticosteroid sensitization drives opioid addiction.

皮质类固醇致敏会导致阿片类药物成瘾。

DOI：
发表时间：
2022-05
期刊：
影响因子：
11
作者：
Carmack, Stephanie A;Vendruscolo, Janaina C M;Adrienne McGinn, M;Miranda;Repunte;Bosse, Gabriel D;Mercatelli, Daniele;Giorgi, Federico M;Fu, Yu;Hinrich, Anthony J;Jodelka, Francine M;Ling, Karen;Messing, Robert
通讯作者：
Messing, Robert

A Corticotropin Releasing Factor Network in the Extended Amygdala for Anxiety.

扩展杏仁核中的促肾上腺皮质激素释放因子网络用于治疗焦虑。

DOI：
发表时间：
2019-02-06
期刊：
影响因子：
0
作者：
Pomrenze, Matthew B;Tovar;Blasio, Angelo;Maiya, Rajani;Giovanetti, Simone M;Lei, Kelly;Morikawa, Hitoshi;Hopf, F Woodward;Messing, Robert O
通讯作者：
Messing, Robert O

Abstinence-dependent dissociable central amygdala microcircuits control drug craving.

戒断依赖性可分离中央杏仁核微电路控制药物渴望。

DOI：
发表时间：
2020-04-07
期刊：
影响因子：
11.1
作者：
Venniro, Marco;Russell, Trinity I;Ramsey, Leslie A;Richie, Christopher T;Lesscher, Heidi M B;Giovanetti, Simone M;Messing, Robert O;Shaham, Yavin
通讯作者：
Shaham, Yavin